UCEDANE Dispersible tablet Ref.[27684] Active ingredients: Carglumic acid

Source: European Medicines Agency (EU)  Revision Year: 2021  Publisher: Eurocept International BV, Trapgans 5, 1244 RL Ankeveen, The Netherlands

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Breast-feeding during the use of carglumic acid is contraindicated (see sections 4.6 and 5.3).

4.4. Special warnings and precautions for use

Therapeutic monitoring

Plasma levels of ammonia and amino acids should be maintained within normal limits. As very few data on the safety of carglumic acid are available, systematic surveillance of liver, renal, cardiac functions and haematological parameters is recommended.

Nutritional management

Protein restriction and arginine supplementation may be indicated in case of low protein tolerance.

4.5. Interaction with other medicinal products and other forms of interaction

No specific interaction studies have been performed.

4.6. Pregnancy and lactation

Pregnancy

For carglumic acid no clinical data on exposed pregnancies are available. Animal studies have revealed minimal developmental toxicity (see section 5.3). Caution should be exercised when prescribing to pregnant women.

Breast-feeding

Although it is not known whether carglumic acid is secreted into human milk, it has been shown to be present in the milk of lactating rats (see section 5.3). Therefore, breast-feeding during the use of carglumic acid is contraindicated (see section 4.3).

4.7. Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Reported adverse reactions are listed below, by system organ class and by frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10) and uncommon (≥1/1,000 to <1/100) 100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Undesirable effects in N-acetylglutamate synthase deficiency:

Investigations

Uncommon: increased transaminases

Skin and subcutaneous tissue disorders

Common: increased sweating

Not known: rash

Undesirable effects in organic acidaemia:

Cardiac disorders

Uncommon: bradycardia

Gastrointestinal disorders

Uncommon: diarrhoea, vomiting

General disorders and Administration site conditions

Uncommon: pyrexia

Skin and subcutaneous tissue disorders

Not known: rash

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

6.2. Incompatibilities

Not applicable.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.